Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Arlette Flore Moguem Soubgui
36  Ergebnisse:
Personensuche X
?
1

Crude SARS-CoV-2 seroprevalence profile by months and healt..:

Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.s003.  , 2024
Link: https://doi.org/10.1371/..
 
?
2

Crude SARS-CoV-2 seroprevalence profile by clinical symptom:

Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.s004.  , 2024
Link: https://doi.org/10.1371/..
 
?
3

Flow diagram of the study:

Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.g001.  , 2024
Link: https://doi.org/10.1371/..
 
?
4

Testing SARS-CoV-2 immune response parameters (IgM, IgG, CD..:

Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.s002.  , 2024
Link: https://doi.org/10.1371/..
 
?
5

Overall variation of CD4+ (A, D), IFN-γ (B, E) and IL-6 (C,..:

Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.g005.  , 2024
Link: https://doi.org/10.1371/..
 
?
6

Clinical value of symptoms for prognostic of IgM seropositi..:

Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.s005.  , 2024
Link: https://doi.org/10.1371/..
 
?
7

Fig 2 -:

Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.g002.  , 2024
Link: https://doi.org/10.1371/..
 
?
8

Univariate logistic regression between SARS-CoV-2 antibodie..:

Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.t002.  , 2024
Link: https://doi.org/10.1371/..
 
?
9

Predictors of the presence of anti-SARS-CoV-2 antibodies am..:

Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.t004.  , 2024
Link: https://doi.org/10.1371/..
 
?
10

Crude prevalence of SARS–CoV–2 antibodies by study sites:

Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.g003.  , 2024
Link: https://doi.org/10.1371/..
 
?
11

Univariate logistic regression between SARS-CoV-2 antibodie..:

Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.t002.  , 2024
Link: https://doi.org/10.1371/..
 
?
12

Predictors of the presence of anti-SARS-CoV-2 antibodies am..:

Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.t004.  , 2024
Link: https://doi.org/10.1371/..
 
?
13

Clinical value of symptoms for prognostic of IgM seropositi..:

Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.s005.  , 2024
Link: https://doi.org/10.1371/..
 
?
14

Variation of CD4+, INF-γ and IL-6 by seropositivity status,..:

Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.g006.  , 2024
Link: https://doi.org/10.1371/..
 
?
15

Ethical clearance of the study: English translation and ori..:

Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.s001.  , 2024
Link: https://doi.org/10.1371/..
 
1-15